“We are the world leader in exploring brain metabolism with the goal of discovering new therapies.“

Frédéric Sedel, 2017


July 22nd, 2019

MedDay Pharmaceuticals to webcast key opinion leader meeting on new treatment strategies for progressive forms of multiple sclerosis tomorrow
Read more

November 09th, 2018

MedDay Pharmaceuticals Announces Full Patient Enrollment for MD1003 Phase III Clinical Trial (SPI2) in Progressive Multiple Sclerosis
Read more

July 26th, 2018

MedDay Appoints Industry Leader Christian Chavy as Chief Executive Officer
Read more


Committed to patients, our passionate teams are investigating brain metabolism therapies, utilizing an innovative approach, with the goal of transforming the lives of people affected by serious neurodegenerative conditions.